Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice
Related Experiment Videos
Insights
Valproate treatment in infant mice reduced key metabolic indicators and brain weight, potentially impacting development and indicating anticonvulsant effects. These findings suggest valproate may cause maturational delay and hepatic toxicity in young animals.
Area of Science:
- Neuroscience
- Developmental Biology
- Biochemistry
Background:
- Valproate is a widely used anticonvulsant medication.
- Its effects on the developing brain, particularly in early life, require further investigation.
- Understanding valproate's impact on infant neurochemistry is crucial for assessing its safety and efficacy.
Purpose of the Study:
- To investigate the biochemical and metabolic effects of valproate administration in infant mice.
- To explore the potential relationship between valproate's metabolic changes and its anticonvulsant action.
- To assess the impact of valproate on brain development and potential hepatic toxicity in neonates.
Main Methods:
- Infant mice (2-4 days old) were administered valproate (100 or 200 mg/kg) subcutaneously daily for 5 days.
- Plasma and brain metabolite levels, including beta-hydroxybutyrate, free fatty acids, glycerol, amino acids (GABA, aspartate, glutamate), and taurine, were analyzed.
- Brain weight, potassium content, and liver glycogen stores were measured.
Main Results:
- Both valproate doses significantly decreased plasma beta-hydroxybutyrate levels.
- High-dose valproate (200 mg/kg) reduced brain weight, brain potassium content, and liver glycogen stores.
- Metabolite changes in the brain indicated reduced glycolytic and citric acid cycle flux, with decreased aspartate and glutamate, and increased taurine.
- Valproate did not increase brain GABA levels.
Conclusions:
- Valproate administration in infant mice alters brain metabolism, potentially contributing to its anticonvulsant effects.
- Observed decreases in brain weight and potassium content, alongside altered metabolite profiles, suggest a possible maturational delay.
- Reduced liver glycogen and ketonemia indicate potential hepatic toxicity, relevant to clinical observations in infants and children.
Abstract:
Infant mice (2 to 4 days old) received valproate (100 or 200 mg per kilogram body weight) subcutaneously once daily for 5 days. Both dosages decreased plasma beta-hydroxybutyrate levels to about one-third of the control value, in the face of normal free fatty acid and glycerol levels. At 200 mg per kilogram of valproate, there were significant decreases in brain weight and brain K content. Both doses produced metabolite changes in brain compatible with a reduced metabolic flux through the glycolytic pathway and the citric acid cycle. Valproate reduced brain aspartate but did not increase brain GABA levels in infant mice. At 200 mg per kilogram of valproate, brain glutamate decreased and taurine levels increased. Two hundred milligrams per kilogram of valproate caused a profound reduction of liver glycogen stores. The apparent decrease in cerebral metabolic rate, reduced glutamate and aspartate, and increased levels of taurine in brain may relate to the anticonvulsant action of valproate. Together with the decreased brain weight and K content, the findings are also compatible with maturational delay. Decreased ketonemia and liver glycogen content may relate to the hepatic toxicity associated with valproate administration in infants and children.